
|Articles|July 15, 2003
Iris-claw myopic IOL shows promise during ongoing FDA trial
Author(s)Cheryl Guttman
San Francisco-In ongoing FDA clinical trial follow-up, the iris-claw myopic IOL (Artisan/Verisyse, Ophtec/AMO) continues to be associated with excellent refractive and visual outcomes along with outstanding safety and high patient satisfaction, said Elizabeth A. Davis, MD, FACS, at the American Society of Cataract and Refractive Surgery annual meeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
AAO 2025: Trial demonstrates safety and efficacy of epithelium-on cross linking
5